LongBio Pharma (1779) investor relations material

Executive summary

• Achieved significant clinical pipeline progress, with over 1,000 patients enrolled across all clinical trials as of the report date.

• Completed Phase III trial for LP-003 in seasonal AR, with BLA accepted by NMPA in August 2026.

• FDA approved clinical trial for LP-003 in peanut allergy, supporting international expansion.

• Presented positive head-to-head Phase II data for LP-003 vs. omalizumab in CSU at AAAAI 2026.

• Initiated multiple Phase II trials for LP-003 (CRSwNP) and LP-005 (PNH, kidney diseases, periodontitis).

Financial highlights

• No revenue generated during the period; pre-revenue biotech status maintained.

• Research and development costs rose 60.8% year-over-year to RMB108.2 million, driven by clinical trial advancement.

• Administrative expenses increased 117.0% year-over-year to RMB24.6 million, mainly due to listing-related professional fees and staff expansion.

• Finance costs dropped sharply to RMB0.6 million from RMB16.3 million, reflecting lower interest on redemption liabilities.

• Net loss widened 43.1% year-over-year to RMB134.8 million.

• Cash and cash equivalents surged to RMB903.8 million as of June 30, 2026, mainly from IPO proceeds.

Outlook and guidance

• Plans to advance LP-003 BLA review and commercialization for seasonal AR, commence Phase III for CSU, and continue Phase II for allergic asthma and CRSwNP.

• Intends to complete Phase II trials for LP-005 in PNH by Q4 2028 and continue trials for kidney diseases and periodontitis.

• Will invest in R&D for bi-functional antibody candidates (LP-00A, LP-00C, LP-00D) and seek NRDL inclusion for LP-003.

• International expansion with LP-003 peanut allergy trial in the US.

• Continued development of LP-005 and preclinical pipeline candidates.